MIRM logo

MIRM Mirum Pharmaceuticals, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$92.49
+0.54 (+0.59%)

Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat …

Market Cap: $6.04Bwww.mirumpharma.com

Price

No data yet.

Social Signal Score

49
5d
—
30d
44
7 mentions
—
60d
51
26 mentions
—
90d
51
30 mentions
—
news: 18 · rss: 10 · marketaux: 2

Analyst Ratings

18 analysts
Buyconsensus
Strong Buy 1Buy 17Hold 0Sell 0Strong Sell 0
Avg price target$154.82+67.4%
Low $130Median $146High $202
Current Consensus

Revenue

$185.72M
$0.00$61.91M$123.81M$185.72M
Sep 2018Sep 2026

Analyst Estimates

FY2025
$-0.25
$-0.47–$-0.08
8 analysts
FY2026
$-15.20
$-15.49–$-14.57
6 analysts
FY2027
$-1.28
$-2.77–$-0.28
6 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Christopher Peetz
Sector
Healthcare
Industry
Biotechnology
Employees
433
Beta
0.49
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
-0.50
www.mirumpharma.com